Harm Reduction and Adaptations Among PWUD in Rural Oregon During COVID-19.
COVID-19
Harm reduction
Opioid use disorder
Rural
Syringe services programs
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
accepted:
15
12
2020
pubmed:
21
1
2021
medline:
28
4
2021
entrez:
20
1
2021
Statut:
ppublish
Résumé
Coronavirus Disease 2019 (COVID-19) may influence HIV/HCV transmission risk behaviors in rural communities. We conducted semi-structured qualitative interviews with people who use drugs (PWUD) in five rural Oregon counties and asked about COVID-19 impact on substance use and harm reduction practices and their advice for improving public health responses. Participants (n = 36) reported using only methamphetamine (52.8%), only heroin (16.7%), or both (30.6%); 75% of participants reported recent injection. Three thematic categories emerged: SSP adaptations and accessibility, PWUD harm reduction practices, and policy suggestions. Participants noted the importance of SSPs to COVID-19 prevention and wellbeing, though some experienced increased barriers, leading to increased risky injection practices. Participants suggested need-based rather than one-for-one exchange, increasing syringe delivery services, encouraging secondary exchange by PWUD, and peers as trusted voices for information exchange. Rapid implementation of policy and practice changes are urgently required to improve SSP access, reinforce safer use, and prevent HIV/HCV and COVID-19 transmission.
Identifiants
pubmed: 33471243
doi: 10.1007/s10461-020-03141-4
pii: 10.1007/s10461-020-03141-4
pmc: PMC7816753
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1331-1339Subventions
Organisme : NCATS NIH HHS
ID : U01 TR002631
Pays : United States
Organisme : NIDA NIH HHS
ID : UH3 DA044831
Pays : United States
Organisme : NIDA NIH HHS
ID : UH3DA044831
Pays : United States
Références
Raker EJ, Zacher M, Lowe SR. Lessons from Hurricane Katrina for predicting the indirect health consequences of the COVID-19 pandemic. Proc Natl Acad Sci USA. 2020;117(23):12595–7.
doi: 10.1073/pnas.2006706117
Volkow N, NIDA. 2020. https://www.drugabuse.gov/about-nida/noras-blog/2020/04/covid-19-potential-implications-individuals-substance-use-disorders.
Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2020;14:1–10.
Ochalek TA, Cumpston KL, Wills BK, Gal TS, Moeller FG. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. JAMA. 2020;324(16):1673–4.
doi: 10.1001/jama.2020.17477
Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176.
doi: 10.1016/j.drugalcdep.2020.108176
Wainwright J, Mikre M, Whitley P, Dawson E, Huskey A, Lukowiak A, et al. Analysis of drug test results before and after the US declaration of a national emergency concerning the COVID-19 outbreak. JAMA. 2020;34(15):1674–6.
doi: 10.1001/jama.2020.17694
Glober N, Mohler G, Huynh P, Arkins T, O’Donnell D, Carter J, et al. Impact of COVID-19 Pandemic on drug overdoses in Indianapolis. J Urban Health. 2020;97(6):802–7.
doi: 10.1007/s11524-020-00484-0
Rodda LN, West KL, LeSaint KT. Opioid overdose-related emergency department visits and accidental deaths during the COVID-19 pandemic. J Urban Health. 2020;97(6):808–13.
doi: 10.1007/s11524-020-00486-y
Farhoudian A, Baldacchino A, Clark N, Gerra G, Ekhtiari H, Dom G, et al. COVID-19 and substance use disorders as brain diseases: recommendations to a comprehensive healthcare response. An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper. Basic Clin Neurosci J. 2020;11(2):133–50.
Marsden J, Darke S, Hall W, Hickman M, Holmes J, Humphreys K, et al. Mitigating and learning from the impact of COVID-19 infection on addictive disorders. Addiction. 2020;115(6):1007–10.
doi: 10.1111/add.15080
Slaunwhite AK, Gan WQ, Xavier C, Zhao B, Buxton JA, Desai R. Overdose and risk factors for coronavirus disease 2019. Drug Alcohol Depend. 2020;212:108047.
doi: 10.1016/j.drugalcdep.2020.108047
Akhtar WZ, Mundt MP, Koepke R, Krechel S, Fiore MC, Seal DW, et al. Prevalence of tobacco use among rural-dwelling individuals who inject drugs. JAMA Netw Open. 2020;3(3):e200493.
doi: 10.1001/jamanetworkopen.2020.0493
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–9.
doi: 10.1001/jama.2020.6775
Karaye IM, Horney JA. The impact of social vulnerability on COVID-19 in the U.S.: an analysis of spatially varying relationships. Am J Prev Med. 2020;59(3):317–25.
doi: 10.1016/j.amepre.2020.06.006
Hunter A, Weekly ADA. Overdose resurgence amid pandemic fuels debate over treatment access measures. 2020;32(24):5–6.
Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):26.
doi: 10.1186/s12954-020-00370-7
Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. Morb Mortal Wkly Rep. 2015;64(48):1337–41.
doi: 10.15585/mmwr.mm6448a3
Bluthenthal RN, Anderson R, Flynn NM, Kral AH. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug Alcohol Depend. 2007;89(2–3):214–22.
doi: 10.1016/j.drugalcdep.2006.12.035
Fernandes RM, Cary M, Duarte G, Jesus G, Alarcao J, Torre C, et al. Effectiveness of needle and syringe Programmes in people who inject drugs—an overview of systematic reviews. BMC Public Health. 2017;17(1):309.
doi: 10.1186/s12889-017-4210-2
Bramson H, Des Jarlais DC, Arasteh K, Nugent A, Guardino V, Feelemyer J, et al. State laws, syringe exchange, and HIV among persons who inject drugs in the United States: history and effectiveness. J Public Health Policy. 2015;36(2):212–30.
doi: 10.1057/jphp.2014.54
Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9:012021.
Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M. Addressing the syndemic of HIV, hepatitis C, overdose, and COVID-19 among people who use drugs: the potential roles for decriminalization and safe supply. J Stud Alcohol Drugs. 2020;81(5):556–60.
doi: 10.15288/jsad.2020.81.556
OHA sees 70% increase in Oregon opioid deaths during April, May [press release]. Oregon Health Authority. 2020.
Guidance about COVID-19 risk for harm reduction and syringe service programs [press release]. Public Health Acute and Communicable Disease Prevention. 2020.
Glick SN, Prohaska SM, LaKosky PA, Juarez AM, Corcorran MA, Des Jarlais DC. The impact of COVID-19 on syringe services programs in the United States. AIDS Behav. 2020;24(9):2466–8.
doi: 10.1007/s10461-020-02886-2
Dombrowski K, Crawford D, Bilal K, Kimberly T. Current rural drug use in the US Midwest. J Drug Abuse. 2016;2(3):2–14.
Grant KM, Kelley SS, Agrawal S, Meza JL, Meyer JR, Romberger DJ. Methamphetamine use in rural Midwesterners. Am J Addict. 2007;16(2):79–84.
doi: 10.1080/10550490601184159
Moy E, Garcia MC, Bastian B, Rossen LM, Ingram DD, Faul M, Massetti GM, Thomas CC, Hong Y, Yoon PW, Iademarco MF. Leading causes of death in Nonmetropolitan and Metropolitan areas—United States, 1999–2014. MMWR Surveill Summ. 2017;66(SS-1):1–8.
doi: 10.15585/mmwr.ss6601a1
Whetten K, Leserman J, Whetten R, Ostermann J, Thielman N, Swartz M, et al. Exploring lack of trust in care providers and the government as a barrier to health service use. Am J Public Health. 2006;96(4):716–21.
doi: 10.2105/AJPH.2005.063255
Room R. Stigma, social inequality and alcohol and drug use. Drug Alcohol Rev. 2005;24(2):143–55.
doi: 10.1080/09595230500102434
Soukup-Baljak Y, Greer AM, Amlani A, Sampson O, Buxton JA. Drug quality assessment practices and communication of drug alerts among people who use drugs. Int J Drug Policy. 2015;26(12):1251–7.
doi: 10.1016/j.drugpo.2015.06.006
WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020 [press release]. World Health Organization 2020.
NIDA. 2020. https://www.drugabuse.gov/news-events/news-releases/2017/08/grants-awarded-to-address-opioid-crisis-in-rural-regions .
International Q. NVivo Qualitative Data Analysis Software. https://qsrinternational.com/nvivo/nvivo-products/ . 1999.
Miles M, Huberman A, Saldana J. Qualitative data analysis: a methods sourcebook. Thousand Oaks: Sage Publishing; 2014.
Guest G, MacQueen K, Namey E. Applied thematic analysis. Thousand Oaks, CA: Sage Publications, Incorporated; 2011.
Bartal A, Pliskin N, Tsur O. Local/global contagion of viral/non-viral information: analysis of contagion spread in online social networks. PLoS One. 2020;15(4):e0230811.
doi: 10.1371/journal.pone.0230811
Hodas NO, Lerman K. The simple rules of social contagion. Sci Rep. 2014;4:4343.
doi: 10.1038/srep04343
Monsted B, Sapiezynski P, Ferrara E, Lehmann S. Evidence of complex contagion of information in social media: an experiment using Twitter bots. PLoS One. 2017;12(9):184148.
doi: 10.1371/journal.pone.0184148
United States COVID-19 Cases and Deaths by State. 2020. https://www.cdc.gov/covid-data-tracker/index.html#cases .